Bioceltix (BCX) Q2 2024 earnings summary

Executive summary

• Submitted a marketing authorization application to the EMA for BCX-CM-J, a stem cell-based veterinary drug for canine osteoarthritis; application validated and under review as of July 2024.

• Clinical trials for BCX-EM (equine arthritis) completed patient recruitment; interim results show 64% efficacy vs. 33% in control.

• BCX-CM-AD (canine atopic dermatitis) clinical trial interim analysis allowed reduction in patient number due to strong efficacy signals.

• Initiated construction of a new large-scale manufacturing facility in Wrocław, targeting 100,000+ annual doses, with completion expected in H2 2026.

• Raised PLN 46.1 million in a successful share issue to fund expansion and ongoing R&D.

Financial highlights

• No revenue from product sales in H1 2024; operations funded by equity and grants.

• Net loss of PLN 8.43 million in H1 2024, compared to PLN 6.40 million loss in H1 2023.

• Operating cash outflow of PLN 6.66 million; net cash inflow from financing activities of PLN 17.26 million.

• Cash position at period end: PLN 20.04 million.

• Book value per share: PLN 9.12 (up from PLN 2.53 at 2023 mid-year).

Outlook and guidance

• Expect continued losses in H2 2024 as R&D and clinical costs remain high.

• Focus on completing clinical trials, submitting further EMA applications, and advancing commercialization partnerships.

• New manufacturing facility to support anticipated market entry and scale-up.